Management ChangeMay 8, 2026, 04:23 PM
iBio Appoints Dr. Elizabeth Stoner to Board; Evert Schimmelpennink Resigns
AI Summary
iBio, Inc. announced the appointment of Dr. Elizabeth Stoner, M.D., M.S., to its Board of Directors and Compensation Committee, effective May 7, 2026. Dr. Stoner brings over 35 years of research and development leadership, including roles at MPM BioImpact, Semma Therapeutics, Rhythm Pharmaceuticals, and Merck Research Laboratories. Concurrently, Evert Schimmelpennink resigned from the Board and Compensation Committee, with his departure not attributed to any disagreement with the company.
Key Highlights
- Dr. Elizabeth Stoner appointed as a Class II director and member of the Compensation Committee, effective May 7, 2026.
- Dr. Stoner's term will expire at iBio's 2028 annual meeting of stockholders.
- She will receive an annual Board fee of $40,000 and a Compensation Committee fee of $7,500 for fiscal year ending June 30, 2026.
- Dr. Stoner is eligible for a one-time option grant vesting over 36 months and other equity awards.
- Evert Schimmelpennink resigned from the Board and Compensation Committee, effective May 7, 2026.
- Mr. Schimmelpennink's resignation was not due to any disagreement with the Company.
- Dr. Stoner is an Entrepreneur Partner at MPM BioImpact and previously held leadership roles at Merck Research Laboratories.
Price Impact
More from IBIO